Manuel Gomes David
@m_gdavidGyn onco & Breast surgeon @icl_lorraine @Univ_Lorraine
Similar User
@HousseinELHAJJ3
@ASGRS_org
@GaSchivardi
@enoralaas
@mdslightfoot
@drsaritaaiims
@smhsiao2
@AiswaryaRamprak
@NawarLatif_MD
@KunnathNeethu
@LimYuHui4
@Virginiefourch
I would like to thank Julia Salleron, Pr Frédéric Marchal and all members from @PSOGI_EC and BIGRENAPE groups for the work! @BMCSurgery #HIPEC #EndometrialCancer #surgery rdcu.be/cEAue
🧬Cancer types and genes associated with germline mutations 👇 @ASCO @OncoAlert @JCOPO_ASCO #cancer #oncology #genetics #MedX
Interesting
🔬 Exciting new #ClinicalTrials alert! #VULCANize2 is comparing two treatment strategies for locally advanced #VulvarCancer: 1️⃣ Primary #chemoradiation 2️⃣ #Neoadjuvant chemotherapy + #surgery 💪 Aiming to improve outcomes & quality of life for patients Read full protocol @…
ATALANTE OS: I'm going to respectfully disagree with the messaging of this presentation. This was a negative trial. PFS was negative. A "clinically meaningful" OS benefit does not make this a positive trial nor should encourage use of CPI in ovarian cancer. If anything -…
A great honor. Re-defining the concept of parametrial anatomy, nerve sparing and radical hysterectomy types with our international team of gynecological oncologists and anatomists. 'Radical hysterectomy is the art of pelvic surgery, Ilker Selcuk MD-PhD' @IJGConline @ESGO_society
Si le dépistage reste un examen essentiel pour détecter un cancer du sein, l’auto-palpation est elle aussi recommandée. Comment s'y prendre? On vous explique
Excited to share our meta-analysis 💥According to the pooled analysis of the PENELOPE-B, PALLAS, MonarchE and NATALEE trials, there is a significant DFS benefit of CDK 4/6 inhibition, especially in stage 3 patients (HR: 0.67) tandfonline.com/doi/full/10.10…
NOW OF: In the final 10-yr survival analysis of the OVHIPEC-1 ph 3 RCT of cytoreductive surgery w/o vs w/ HIPEC in pts with adv ovarian cancer, median PFS was 10·7 months (95% CI 9·6–12·0) vs 14·3 months (12·0–18·5); HR 0·63 [95% CI 0·48–0·83], p=0·0008). thelancet.com/journals/lanon…
An easy, fast, and accurate way for implementing the standards of care for the management of patients with endometrial carcinoma into daily clinical practice: the ESGO mobile app ijgc.bmj.com/content/33/8/1…
Platinum‐based chemotherapy for early triple‐negative breast cancer (Cochrane Database) 20 studies, 4.688 patients DFS and OS (Carbo)⬆️ Neoadj➡️HR: 0.63 and 0.69 Adj➡️HR 0.69 and 0.70 📌 Regardless of BRCA, HRD, LN positivity and anthracycline cochranelibrary.com/cdsr/doi/10.10…
💡 Nouvel outil indispensable en RCP gynéco pour retrouver en quelques clics les recommandations #ESGO et #ESTRO de traitement adjuvant des cancers de l’endomètre 📲 disponible dans [Espace Pro] d’@OncoClic
🎥 Découvrez aujourd’hui notre nouvel outil Adjuvant Endomètre sur l’application Oncoclic! 📱Oncoclic, la première application en oncologie. 💡Toutes les informations sur les essais cliniques en oncologie disponibles dans la rubrique #ACTIS #cancer #oncologie #oncology #clinical
#ovariancancer: @myESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† - @Annals_Oncology @ESGO_society @IGCSociety @GynMe4 @gyncsm @OncoAlert @weoncologists annalsofoncology.org/article/S0923-…
Cancer Statistics 2023 from @AmericanCancer is now published in @CAonline #OpenAccess acsjournals.onlinelibrary.wiley.com/doi/full/10.33… @OncoAlert
🇨🇦 study finds 9% of patients with endometrial intraepithelial neoplasia had high-intermediate to high-risk disease on final pathology: SLN mapping useful @Gyne_Oncology @SGO_org @IGCSociety @ESGO_society @SOGCorg @OncoAlert @mcgillu sciencedirect.com/science/articl…
📢🥁By popular demand presenting the TOP Oncology publications of 2022. PS: List not exhaustive - so feel free to tag & add important papers to the list @OncoAlert @NEJM @TheLancetOncol @Annals_Oncology @NatureMedicine @Nature @CD_AACR
Chaque année, je crée un nouveau document dans lequel je note tous les trucs intéressants que j'apprends au fil des mois. Voici une petite selection de mon doc 2022⬇️
Oral selinexor in combination with weekly paclitaxel demonstrates promising clinical activity with manageable toxicity in ovarian cancer patients @ShannonWestin @SGO_org @IGCSociety @ESGO_society @ASCO @myESMO @OncoAlert sciencedirect.com/science/articl…
Menopausal estrogen-only therapy associated with 33% lower odds of having macroscopic residual disease following primary cytoreductive surgery🚨What’s the mechanism? 🤨 @SGO_org @IGCSociety @ESGO_society @OncoAlert @ASCO @myESMO sciencedirect.com/science/articl…
Robotic pelvic and para-aortic retroperitoneal lymph nodes staging for early-stage epithelial ovarian cancer ijgc.bmj.com/content/early/…
United States Trends
- 1. Ohio State 23,1 B posts
- 2. Indiana 33,1 B posts
- 3. Wayne 121 B posts
- 4. #daddychill 2.315 posts
- 5. $AROK 5.603 posts
- 6. Howard 22,2 B posts
- 7. Ryan Day 3.546 posts
- 8. Gus Johnson N/A
- 9. Hoosiers 7.028 posts
- 10. Buckeyes 6.318 posts
- 11. DJ Lagway 1.677 posts
- 12. $MOOCAT 7.273 posts
- 13. #iufb 3.909 posts
- 14. UMass 2.755 posts
- 15. Chip Kelly N/A
- 16. Surgeon General 107 B posts
- 17. Cody Simon N/A
- 18. Carnell Tate N/A
- 19. Neil 33,2 B posts
- 20. Maddison 12,3 B posts
Who to follow
-
Houssein EL HAJJ
@HousseinELHAJJ3 -
Asian Society for Gynecologic Robotic Surgery
@ASGRS_org -
Gabriella Schivardi
@GaSchivardi -
Enora Laas-Faron
@enoralaas -
Michelle Lightfoot, MD MPH
@mdslightfoot -
Sarita Sharma
@drsaritaaiims -
Sheng-Mou Hsiao
@smhsiao2 -
Aiswarya Ramprakash
@AiswaryaRamprak -
Nawar Latif, MD, MPH, MSCE
@NawarLatif_MD -
Neethu Kunnath
@KunnathNeethu -
Lim Yu Hui
@LimYuHui4 -
Virginie fourchotte
@Virginiefourch
Something went wrong.
Something went wrong.